Illumina experienced strong upward price momentum driven primarily by major price target increases from prominent Wall Street research firms. RBC Capital significantly raised its target price on the stock while reiterating an Outperform rating, citing an accelerating inflection in clinical sequencing demand and a broader valuation re-rating across the life sciences ecosystem. Research analysts highlighted that high-throughput sequencing and genomic tools companies are increasingly recognized as essential infrastructure beneficiaries of artificial intelligence applications in drug discovery and molecular diagnostics. Positive revisions from additional investment banks further…